Women between the ages of 65 and 75 with APOE ε3/ε4 have an increased risk of developing mild cognitive impairment (MCI) or AD compared with men (Neu et al., 2017), and the association between APOE ε4 and cerebrospinal fluid (CSF) tau level is stronger among women than men (Hohman et al., 2018). This evidence concerns the gene APOE and Alzheimer disease.